Three-year data from the DALIAH trial: Recombinant interferon alpha-2 VS hydroxyurea in patients with myeloproliferative neoplasms
BestPractice | Jun 2019 | | EHA 2019
The DALIAH trial is an ongoing investigator initiated Danish multicenter randomized controlled phase III clinical trial. This study shows, that at 36 months the clinicohematologicalORR was higher in patients with essential thrombocythemia, polycythemia vera and prefibroticmyelofibrosis treated with hydroxyurea. Click and hear Trine Alma Knudsen explain the new data.